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Sir,
We would like to thank Daniel B Costa, MD for his interest in
our manuscript.
In his letter, Dr Costa cited the two retrospective studies (Riely
et al, 2006; Jackman et al, 2006) showing prolonged time to
progression and overall survival (OS) of non-small cell lung cancer
patients with exon 19 deletions when compared with L858R
patients given epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitors, and raised the important issue of clinical
differences between these two types of mutations. As Dr Costa also
mentioned, however, the two Japanese prospective trials (including
our own) have shown no significant differences in response rate
between these mutation types (Asahina et al, 2006; Inoue et al,
2006). In our trial, where individual data for progression-free
survival (PFS) and OS were available, median PFS for exon 19
deletion was 8.3 months and two of the three patients with L858R
mutation were alive and progression-free after more than 11.7
months, whereas median OS has not been reached in either group.
The lack of observed higher efficacy against exon 19 deletions
compared with L858R mutations in the Japanese trials may be due
to insufficient numbers of patients, as these Japanese trials were
not designed to determine differences in EGFR genotypes.
However, the conflicting results could also reflect ethnic differ-
ences. In addition to our tials, we calculated median PFS for each
type of mutation from the retrospective data provided by Chou
et al (2005) and Zhang et al (2005), as both studies were conducted
in East Asian countries. Median PFS was 7.8 months in patients
with exon 19 deletions and 7.6 months in patients with L858R in
the former study, and 6.4 months and 10.2 months in the latter
study, respectively. Although we could not calculate precise OS
from those data, median PFS of patients with L858R seemed
similar to or longer than that for patients with exon 19 deletions in
the East Asian studies.
Conflicting results are thus apparent regarding differences in
these two mutations and further data collection is required.
Differences in tyrosine phosphorylation status reported from the
in vitro study by Chen et al (2006) suggest the existence of clinical
differences between patients with these two mutations. We hope
that subsequent randomised phase III trials in different ethnic
populations will answer this question.
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